Eric Suto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eric Suto has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Wyne P. Lee
Translational Immunology Department, Genentech, South San Francisco, USA
4 shared publications - Cary D. Austin
Department of Pathology, Genentech, A Member of the Roche Group
3 shared publications John Liu
Department of Translational Immunology, Genentech, South San Francisco, USA
3 shared publications- Nico Ghilardi
Genentech, Inc. , 1 DNA Way , South San Francisco , California 94080 , United States
3 shared publications Wyne P. Lee
Department of Translational Immunology, Genentech, South San Francisco, USA
3 shared publications- Andres Paler-Martinez
Affiliation Dept. Translational Immunology, Genentech, South San Francisco, CA, United States of America
2 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by Springer Nature in Nature
- Vol. 648 (8093) , E11
Author Correction: Inhibiting membrane rupture with NINJ1 antibodies limits tissue injury
- 27 November 2025
- Published by Springer Nature in Nature
- Vol. 648 (8093) , E11
Open AccessAuthor Correction: Inhibiting membrane rupture with NINJ1 antibodies limits tissue injury
- Top Cited PapersOpen Access
- 17 May 2023
- Published by Springer Nature in Nature
- Vol. 618 (7967) , 1072-1077
Inhibiting membrane rupture with NINJ1 antibodies limits tissue injury
Plasma membrane rupture (PMR) in dying cells undergoing pyroptosis or apoptosis requires the cell-surface protein NINJ1 1 . PMR releases pro-inflammatory cytoplasmic molecules, collectively called damage-associated molecular patterns (DAMPs), that activate immune cells. Therefore, inhibiting NINJ1 and PMR may limit the inflammation that is associated with excessive cell death. Here we describe an anti-NINJ1 monoclonal antibody that specifically targets mouse NINJ1 and blocks oligomerization of NINJ1, preventing PMR. Electron microscopy studies showed that this antibody prevents NINJ1 from forming oligomeric filaments. In mice, inhibition of NINJ1 or Ninj1 deficiency ameliorated hepatocellular PMR induced with TNF plus d -galactosamine, concanavalin A, Jo2 anti-Fas agonist antibody or ischaemia–reperfusion injury. Accordingly, serum levels of lactate dehydrogenase, the liver enzymes alanine aminotransaminase and aspartate aminotransferase, and the DAMPs interleukin 18 and HMGB1 were reduced. Moreover, in the liver ischaemia–reperfusion injury model, there was an attendant reduction in neutrophil infiltration. These data indicate that NINJ1 mediates PMR and inflammation in diseases driven by aberrant hepatocellular death.
- 17 May 2023
- Published by Springer Nature in Nature
- Vol. 618 (7967) , 1072-1077
Top Cited PapersOpen AccessInhibiting membrane rupture with NINJ1 antibodies limits tissue injury
Plasma membrane rupture (PMR) in dying cells undergoing pyroptosis or apoptosis requires the cell-surface protein NINJ1 1 . PMR releases pro-inflammatory cytoplasmic molecules, collectively called damage-associated molecular patterns (DAMPs), that activate immune cells. Therefore, inhibiting NINJ1 and PMR may limit the inflammation that is associated with excessive cell death. Here we describe an anti-NINJ1 monoclonal antibody that specifically targets mouse NINJ1 and blocks oligomerization of NINJ1, preventing PMR. Electron microscopy studies showed that this antibody prevents NINJ1 from forming oligomeric filaments. In mice, inhibition of NINJ1 or Ninj1 deficiency ameliorated hepatocellular PMR induced with TNF plus d -galactosamine, concanavalin A, Jo2 anti-Fas agonist antibody or ischaemia–reperfusion injury. Accordingly, serum levels of lactate dehydrogenase, the liver enzymes alanine aminotransaminase and aspartate aminotransferase, and the DAMPs interleukin 18 and HMGB1 were reduced. Moreover, in the liver ischaemia–reperfusion injury model, there was an attendant reduction in neutrophil infiltration. These data indicate that NINJ1 mediates PMR and inflammation in diseases driven by aberrant hepatocellular death.
- Top Cited PapersOpen Access
- 23 February 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (4)
A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment
Despite the development of effective therapies, a substantial proportion of asthmatics continue to have uncontrolled symptoms, airflow limitation, and exacerbations. Transient receptor potential cation channel member A1 (TRPA1) agonists are elevated in human asthmatic airways, and in rodents, TRPA1 is involved in the induction of airway inflammation and hyperreactivity. Here, the discovery and early clinical development of GDC-0334, a highly potent, selective, and orally bioavailable TRPA1 antagonist, is described. GDC-0334 inhibited TRPA1 function on airway smooth muscle and sensory neurons, decreasing edema, dermal blood flow (DBF), cough, and allergic airway inflammation in several preclinical species. In a healthy volunteer Phase 1 study, treatment with GDC-0334 reduced TRPA1 agonist-induced DBF, pain, and itch, demonstrating GDC-0334 target engagement in humans. These data provide therapeutic rationale for evaluating TRPA1 inhibition as a clinical therapy for asthma.
- 23 February 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (4)
Top Cited PapersOpen AccessA TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment
Despite the development of effective therapies, a substantial proportion of asthmatics continue to have uncontrolled symptoms, airflow limitation, and exacerbations. Transient receptor potential cation channel member A1 (TRPA1) agonists are elevated in human asthmatic airways, and in rodents, TRPA1 is involved in the induction of airway inflammation and hyperreactivity. Here, the discovery and early clinical development of GDC-0334, a highly potent, selective, and orally bioavailable TRPA1 antagonist, is described. GDC-0334 inhibited TRPA1 function on airway smooth muscle and sensory neurons, decreasing edema, dermal blood flow (DBF), cough, and allergic airway inflammation in several preclinical species. In a healthy volunteer Phase 1 study, treatment with GDC-0334 reduced TRPA1 agonist-induced DBF, pain, and itch, demonstrating GDC-0334 target engagement in humans. These data provide therapeutic rationale for evaluating TRPA1 inhibition as a clinical therapy for asthma.
- Open Access
- 14 January 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (1) , e0244439
The peptide symporter SLC15a4 is essential for the development of systemic lupus erythematosus in murine models
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease representing a serious unmet medical need. The disease is associated with the loss of self-tolerance and exaggerated B cell activation, resulting in autoantibody production and the formation of immune complexes that accumulate in the kidney, causing glomerulonephritis. TLR7, an important mediator of the innate immune response, drives the expression of type-1 interferon (IFN), which leads to expression of type-1 IFN induced genes and aggravates lupus pathology. Because the lysosomal peptide symporter slc15a4 is critically required for type-1 interferon production by pDC, and for certain B cell functions in response to TLR7 and TLR9 signals, we considered it as a potential target for pharmacological intervention in SLE. We deleted the slc15a4 gene in C57BL/6, NZB, and NZW mice and found that pristane-challenged slc15a4-/- mice in the C57BL/6 background and lupus prone slc15a4-/- NZB/W F1 mice were both completely protected from lupus like disease. In the NZB/W F1 model, protection persisted even when disease development was accelerated with an adenovirus encoding IFNα, emphasizing a broad role of slc15a4 in disease initiation. Our results establish a non-redundant function of slc15a4 in regulating both innate and adaptive components of the immune response in SLE pathobiology and suggest that it may be an attractive drug target.
- 14 January 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (1) , e0244439
Open AccessThe peptide symporter SLC15a4 is essential for the development of systemic lupus erythematosus in murine models
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease representing a serious unmet medical need. The disease is associated with the loss of self-tolerance and exaggerated B cell activation, resulting in autoantibody production and the formation of immune complexes that accumulate in the kidney, causing glomerulonephritis. TLR7, an important mediator of the innate immune response, drives the expression of type-1 interferon (IFN), which leads to expression of type-1 IFN induced genes and aggravates lupus pathology. Because the lysosomal peptide symporter slc15a4 is critically required for type-1 interferon production by pDC, and for certain B cell functions in response to TLR7 and TLR9 signals, we considered it as a potential target for pharmacological intervention in SLE. We deleted the slc15a4 gene in C57BL/6, NZB, and NZW mice and found that pristane-challenged slc15a4-/- mice in the C57BL/6 background and lupus prone slc15a4-/- NZB/W F1 mice were both completely protected from lupus like disease. In the NZB/W F1 model, protection persisted even when disease development was accelerated with an adenovirus encoding IFNα, emphasizing a broad role of slc15a4 in disease initiation. Our results establish a non-redundant function of slc15a4 in regulating both innate and adaptive components of the immune response in SLE pathobiology and suggest that it may be an attractive drug target.
- Open Access
- 2 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 13 (634)
The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells
Inhibiting the kinase IRAK4 may suppress a multicellular autoinflammatory loop in patients with lupus.
- 2 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 13 (634)
Open AccessThe kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells
Inhibiting the kinase IRAK4 may suppress a multicellular autoinflammatory loop in patients with lupus.
- 21 November 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (468)
Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma
Inhalation of a Janus kinase 1 inhibitor suppressed lung inflammation without systemic side effects in rodent models of asthma.
- 21 November 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (468)
Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma
Inhalation of a Janus kinase 1 inhibitor suppressed lung inflammation without systemic side effects in rodent models of asthma.
- Open Access
- 4 August 2017
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 214 (9) , 2611-2628
Progranulin deficiency causes impairment of autophagy and TDP-43 accumulation
Loss-of-function mutations in GRN cause frontotemporal dementia (FTD) with transactive response DNA-binding protein of 43 kD (TDP-43)–positive inclusions and neuronal ceroid lipofuscinosis (NCL). There are no disease-modifying therapies for either FTD or NCL, in part because of a poor understanding of how mutations in genes such as GRN contribute to disease pathogenesis and neurodegeneration. By studying mice lacking progranulin (PGRN), the protein encoded by GRN, we discovered multiple lines of evidence that PGRN deficiency results in impairment of autophagy, a key cellular degradation pathway. PGRN-deficient mice are sensitive to Listeria monocytogenes because of deficits in xenophagy, a specialized form of autophagy that mediates clearance of intracellular pathogens. Cells lacking PGRN display reduced autophagic flux, and pathological forms of TDP-43 typically cleared by autophagy accumulate more rapidly in PGRN-deficient neurons. Our findings implicate autophagy as a novel therapeutic target for GRN-associated NCL and FTD and highlight the emerging theme of defective autophagy in the broader FTD/amyotrophic lateral sclerosis spectrum of neurodegenerative disease.
- 4 August 2017
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 214 (9) , 2611-2628
Open AccessProgranulin deficiency causes impairment of autophagy and TDP-43 accumulation
Loss-of-function mutations in GRN cause frontotemporal dementia (FTD) with transactive response DNA-binding protein of 43 kD (TDP-43)–positive inclusions and neuronal ceroid lipofuscinosis (NCL). There are no disease-modifying therapies for either FTD or NCL, in part because of a poor understanding of how mutations in genes such as GRN contribute to disease pathogenesis and neurodegeneration. By studying mice lacking progranulin (PGRN), the protein encoded by GRN, we discovered multiple lines of evidence that PGRN deficiency results in impairment of autophagy, a key cellular degradation pathway. PGRN-deficient mice are sensitive to Listeria monocytogenes because of deficits in xenophagy, a specialized form of autophagy that mediates clearance of intracellular pathogens. Cells lacking PGRN display reduced autophagic flux, and pathological forms of TDP-43 typically cleared by autophagy accumulate more rapidly in PGRN-deficient neurons. Our findings implicate autophagy as a novel therapeutic target for GRN-associated NCL and FTD and highlight the emerging theme of defective autophagy in the broader FTD/amyotrophic lateral sclerosis spectrum of neurodegenerative disease.